South Africa enters phase 2 of Covid-19 vaccine trial
Loading player...
Wits University has begun a second Covid-19 vaccine trial and screening of participants for the NVX-CoV2373.
The phase 2 trial in South Africa will evaluate if the nanoparticle S-protein, in the Covid-19 vaccine known as NVX-CoV237, protects against Covid-19 disease in adults aged 18-64 years old.
On line is Dean -elect, Faculty of Health Sciences at Wits University, Professor Shabir Madhi.
The phase 2 trial in South Africa will evaluate if the nanoparticle S-protein, in the Covid-19 vaccine known as NVX-CoV237, protects against Covid-19 disease in adults aged 18-64 years old.
On line is Dean -elect, Faculty of Health Sciences at Wits University, Professor Shabir Madhi.
